dacarbazine,brentuximab,doxorubicin hydrochloride,nivolumab,pegfilgrastim,vinblastine sulfate,filgrastim
amgen,seagen,bms
['nivolumab', 'lymphoma', 'nivo', 's1826', 'lymsm', 'hodgkin']
patients with advanced-stage hodgkin lymphoma who received nivolumab plus avd experienced a 1-year estimated progression-free survival rate of 94% meeting the primary end point of the phase 3 swog s1826 trial. #asco23 #oncology #nursing #lymsm 
Capturing the voice of nursing professionals in the oncology news landscape.